Ocumension Therapeutics 1477

HKEX · Hong Kong SAR China · Commercial Services

HKD 5.03-0.05 (-1.08%)

Market open· Oct 2, 2026, 7:00 AM UTC· HKD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Ocumension Therapeutics 1477

HKEX · Hong Kong SAR China · Commercial Services

HKD 5.03-0.05 (-1.08%)

Market open· Oct 2, 2026, 7:00 AM UTC· HKD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-41.24% · 6MFull-screen chart

Open HKD 5.40High HKD 5.40Low HKD 4.88Close HKD 5.03Volume 387.77K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: HKD 5.09
Day range: HKD 4.88 – HKD 5.40
52-week range: HKD 4.04 – HKD 9.01
Volume: 387.77K
Market cap: HKD 4.15B
Next earnings date: 2027-03-19
Avg. volume (1Y): 986.88K

Performance

1 week

-5.15%

1 month

-2.64%

3 months

+0.91%

6 months

-40.20%

Year to date

-34.11%

1 year

-41.95%

Total return, dividends included.

Company profile

Sector: Commercial Services
Industry: Miscellaneous Commercial Services
Country: Hong Kong SAR China
Exchange: HKEX
Shares outstanding: 823.01M
Employees: 552
ISIN: KYG674111011
Beta: 1.12

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceJul 01, 2026

Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment

Press Release Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment NCX 470 New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) by exclusive licensee Kowa Company, Ltd. (Kowa) for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension€3 million milestone payment due to Nicox, with a further milestone payment due upon approvalSubmission based on posit

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.